Navigation Links
A Collaboration to Find New Tools to Fight Leukemia

Mayo Clinic Cancer Center, working in collaboration with Ohio State University Comprehensive Cancer Center//, presented evidence Sunday that a novel regimen of three chemotherapy drugs, pentostatin, cyclophosphamide and rituximab, resulted in significant clinical response in patients with previously untreated chronic lymphocytic leukemia (CLL). Lead researcher and Mayo Clinic hematologist Neil E. Kay, M.D., presented these findings at the 2006 American Society of Hematology Annual Meeting in Orlando.

“Chronic lymphocytic leukemia is incurable, but continues to be made more manageable with the advent of powerful new chemoimmunotherapy tools,” says Dr. Kay. “We and our collaborators at Ohio State University, in particular Dr. Michael Grever, have done previous research on pentostatin that led us to believe there would be success with this regimen, and are pleased with the results.”

Regimens using rituximab are common for CLL patients, says Dr. Kay, and his team decided to build upon that knowledge and their understanding of the highly potent chemotherapeutic antibiotic pentostatin to try to develop an even better treatment option. The investigators initiated a trial of three weeks (one cycle) of combined chemotherapy drugs pentostatin (P), cyclophosphamide (C) and rituximab (R) repeated in six cycles for 64 symptomatic but previously untreated patients. Patients in the study also received one year of prophylactic sulfamethoxazole-trimethoprim (anti-infection drug) and acyclovir (antiviral drug) along with the PCR treatment.

The researchers reviewed study participants’ prognostic status and divided the patients into risk categories at the beginning of the study, using a number of different prognostic evaluation tools to describe them, including the Rai stages (clinical levels of disease progression), CD38 and ZAP-70 (overexpressed proteins found in CLL cells), IgVH (mutational status of the immunoglobulin gene occurring in CLL patien ts), and FISH panel assessments (fluorescent probes on the chromosomes to determine common recurring genetic mutations in CLL). The majority of the patients were in high-risk categories; they had significant disease progression and/or a high expectation of rapid advancement of disease.

Following treatment, Dr. Kay’s team found that 91 percent of the patients experienced positive clinical responses (experienced improvement in their condition) to the treatment based on the National Cancer Institute’s Working Group criteria for responses. Forty-one percent achieved complete response, 22 percent experienced nodular partial response and 28 percent partial response, with the average patient’s disease currently estimated to being in response for 32.6 months. The researchers also found that bone marrow suppression and/or infections were minimal.

The prognostic variables that normally indicate likelihood of poor response to treatment appeared to be negated by the treatment --only one genetic defect (deletion of the p arm of chromosome 17) was found to prevent complete response or nodular partial response; the other risk factors did not diminish treatment effectiveness. Also, the researchers found that the regimen was equally effective in young and elderly (over age 70) patients.

“We are very pleased with the results of this study,” says Dr. Kay. “This is a new, viable option for high-risk patients who might not have had much hope before, and it’s especially exciting that it works for patients of all age groups.”

Chronic lymphocytic leukemia is a blood and bone marrow cancer that affects 10,000 new patients each year in the United States. It is called chronic leukemia because it progresses more slowly than acute leukemia, and lymphocytic because it affects a group of white blood cells (lymphocytes), an important component of the immune system which typically fights infection.


Related medicine news :

1. Collaborations planned between British Organization and Indian health care industry
2. Crusade Against Cancer: Collaborations On The Anvil
3. Mayo Clinic and Indian Health Service Form Clinical Practice Collaboration
4. International Collaboration Takes Aim at Rabies
5. British Medical Association Plans Collaboration With India
6. British Medical Association Plans Collaboration With India
7. LondonMet Keen on Widening Research Collaborations With India
8. New Tools To Identify Flu Strains
9. Is There a Connection between Hearing loss and High-speed Dental Tools?
10. Software Tools & Fonts in Seven Indian Languages
11. ‘Dirty’ and Dangerous Tools Put Full Stop to Operatin
Post Your Comments:

(Date:11/25/2015)... IL (PRWEB) , ... November 25, 2015 , ... ... to six decades of music, friendships, and learning in its 65th Anniversary Brillianteen ... held Dec. 5-6. , For 65 years, Brillianteen has been a ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Today, Mothers ... our nation’s roadways has dropped below 10,000 for the first time since 2011. In ... 2013. , According to data released by the National Highway Traffic Safety Administration (NHTSA), ...
(Date:11/25/2015)... ... November 25, 2015 , ... "When ... that regular bras were incredibly uncomfortable," said an inventor from Bronx, N.Y. "In ... She developed the patent-pending RECOVERY BRA for added comfort and support. The bra ...
(Date:11/25/2015)... ... , ... Many people know of the common symptoms of low thyroid hormone ... But many people who find their cholesterol levels and weight are creeping up are ... if they don’t have any of the other symptoms. , Thyroid hormone plays a ...
(Date:11/25/2015)... ... November 25, 2015 , ... Students and parents have something to be thankful ... Create Real Impact awards. California Casualty is proud to support the contest ... distracted and reckless driving, the number one killer of young drivers. , Almost ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 25, 2015 - Will Also ... (CME) --> - Will ... Education (CME) --> - Will ... Continuing Medical Education (CME) Elsevier , ... services, will feature latest diagnostic imaging textbooks and decision support tools, ...
(Date:11/24/2015)... 25, 2015 The hope of ... failure of IVF cycles. After failure of over 15 ... had lost all hopes that she would be able to conceive ever. But finally optimism ... conceived after failure of over 15 IVF cycles. ... they decided to take one last attempt with Gaudium IVF Center in ...
(Date:11/24/2015)... 24, 2015  Array BioPharma Inc. (Nasdaq: ... Officer, Ron Squarer , will present at ... York.  The public is welcome to participate in ... BioPharma website.Event:Piper Jaffray Annual Healthcare ConferencePresenter:  , Ron ... 2015Time:1:30 p.m. Eastern Time Webcast: , ...
Breaking Medicine Technology: